AtriCure Q3 revenue +15.8% to $134.3M, net loss narrows to $0.3M; raises 2025 outlook

AtriCure, Inc.

2025-Q3 EPS reported -$0.28 revenue$394,028,000

Revenue of $134.3M (+15.8% YoY); U.S. $109.3M (+14.5%), international $25.0M (+22.0%).
Net loss of $0.3M ($0.01 diluted EPS) improves $7.6M YoY; adjusted EBITDA $17.8M (+$9.9M).
Gross margin 75.5% (+59 bps) on favorable product mix; operating income $0.2M vs loss of $7.4M.
Company raises full-year 2025 financial outlook (specific guidance numbers not disclosed in press release).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.